The Good and Bad of Those Ubiquitous Drug Ads
In this column for The Wall Street Journal's Think Tank, Drew Altman examines the public’s mixed views about prescription drug ads and their impact on prescribing patterns, based on a new survey.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
In this column for The Wall Street Journal's Think Tank, Drew Altman examines the public’s mixed views about prescription drug ads and their impact on prescribing patterns, based on a new survey.
This month’s Kaiser Health Tracking Poll finds that the affordability of prescription drugs continues to be at the top of the public’s priority list for the President and Congress, picked by majorities across political parties. Issues specific to the ACA, such as repealing provisions of the law or repealing the law entirely, fall much lower on the list. The survey also probes the public's experiences with drug advertisements. A large majority (82%) report they’ve seen…
28% of Public Report Asking Doctor about a Drug They Saw Advertised, and 12% Say Their Doctor Prescribed It Few Workers Expect Raises if Employers Reduce Health Benefits to Avoid Cadillac Tax as Many Economists Predict With some presidential candidates laying out details of their health care platforms, the cost of prescription drugs remains at the top of the public's health care priority list for the President and Congress, the October Kaiser Health Tracking Poll…
This report provides an in depth examination of the changes taking place in state Medicaid programs across the country. The findings in this report are drawn from the 15th annual budget survey of Medicaid officials in all 50 states and the District of Columbia conducted by the Kaiser Commission on Medicaid and the Uninsured and Health Management Associates (HMA), with the support of the National Association of Medicaid Directors. This report highlights policy changes implemented…
Second Analysis Finds Modest Shifts in Medicare Advantage Plan Options When Medicare's 2016 open enrollment begins Oct. 15, current enrollees in stand-alone Medicare Part D plans are projected to face an average 13 percent increase in premiums if they remain in their current plan for 2016, a new analysis finds. Medicare Part D: A First Look at Plan Offerings in 2016 finds that for the coming year, the average beneficiary will have a choice of…
During the Medicare open enrollment period, beneficiaries have the opportunity to enroll in a plan that provides Part D prescription drug coverage, either a stand-alone prescription drug plan (PDP) to supplement traditional Medicare, or a Medicare Advantage drug plan. This issue brief provides an overview of the 2016 PDP marketplace, focusing on key changes from 2015, based on analysis of data from the Centers for Medicare & Medicaid Services. It presents analysis of PDP availability,…
With Medicare Part D nearing the end of its tenth year, the program -- which now provides drug coverage to 72 percent of all Medicare beneficiaries -- has experienced no growth in average premiums in recent years but some notable increases in cost-sharing, according to a new report from the Kaiser Family Foundation. At a time of heightened public concern about the cost of prescription drugs, the report, Medicare Part D at Ten Years: The…
Since 2006, Medicare beneficiaries have had access through Medicare Part D to prescription drug coverage offered by private plans, either stand-alone prescription drug plans (PDPs) or Medicare Advantage prescription drug plans (MA-PD plans). Now in its tenth year, Part D has evolved due to changes in the private plan marketplace and the laws and regulations that govern the program. This report presents findings from an analysis of the Medicare Part D marketplace in 2015 and…
In his latest column for The Wall Street Journal’s Think Tank, Drew Altman examines the trends that may be leading to a rise in consumer cost issues on the health agenda. All previous columns by Drew Altman are available online.
In this column for The Wall Street Journal’s Think Tank, Drew Altman examines the trends that may be leading to a rise in consumer cost issues on the health agenda.
© 2026 KFF